Date: June 12, 2026

Event Announcement

Suven Life Sciences Limited announced it will present three scientific posters at SLEEP-2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), LLC, being held in Baltimore, USA from June 14-17, 2026. The APSS is a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. The SLEEP meeting is described as the premier clinical and scientific meeting focused on sleep medicine, sleep and circadian research, and sleep health, featuring more than 140 exhibits, 1,500 research abstract presentations, and 5,000 attendees, speakers, and exhibitors.

Poster Presentations Details

The presentations will focus on the clinical advancement of Samelisant (SUVN-G3031), the company's investigational treatment for Central Nervous System (CNS) disorders:

  • Samelisant (SUVN-G3031) Demonstrates Significant Reduction in Excessive Daytime Sleepiness in Patients with Narcolepsy: Phase-2 Results (Presentation Date: June 15, 2026; Poster #374)
  • Study Design and Rationale for a Phase-2 Study of Samelisant (SUVN-G3031) for the Treatment of Cataplexy in Patients with Type 1 Narcolepsy (Presentation Date: June 15, 2026; Poster #368)
  • Phase-3 Clinical Development of Samelisant: Rationale and Study Design for Treating Excessive Daytime Sleepiness in Patients with Narcolepsy (Presentation Date: June 16, 2026; Poster #332)

The presentations will include positive Phase-2 efficacy data in excessive daytime sleepiness (EDS), the rationale and design of a Phase-2 study for cataplexy in Type 1 narcolepsy, and the Phase-3 development strategy for Samelisant in patients with narcolepsy (AWAKE study).

Strategic Activities

Members of Suven's scientific team are scheduled to hold several meetings at Suven Exhibit booth #1034 with Phase-3 study Principal Investigators, Key Opinion Leaders (KOLs), and potential partnering companies during the event.

Company Background

Suven Life Sciences Limited is described as a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders. The company has a portfolio of advanced stage clinical candidates and research programs designed for CNS disorders including Alzheimer's disease, Sleep disorders, Major depressive disorders, Parkinson's disease, Schizophrenia, Pain disorders, and Gastrointestinal disorders.

Clinical Pipeline Overview

The release provides details on Suven's clinical stage assets:

  • Masupirdine (SUVN-502): For treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing)
  • Samelisant (SUVN-G3031): For excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for Cataplexy and pivotal Phase-3 study for EDS are in planning)
  • Ropanicant (SUVN-911): For MDD (Open-label Phase 2a study completed; Double blind randomized Placebo controlled Phase-2b study recruitment completed)
  • Usmarapride (SUVN-D4010): For cognitive disorders (Phase-2 study in planning)
  • SUVN-I6107: For cognitive disorders (Phase-1 study in progress)

The company also has 7 projects in research pipeline across multiple indications and owns all intellectual property rights for its assets in all major markets.